CHICAGO, Feb. 8 /PRNewswire-FirstCall/ -- The Female Health Company announced today that it has appointed Donna Felch as Vice President and Chief Financial Officer reporting to O.B. Parrish, Chairman of the Board of Directors.
Ms. Felch has significant financial management experience, primarily with high growth companies in the pharmaceutical industry. Prior to joining Female Health, Ms. Felch was Vice President and Treasurer of American Pharmaceutical Partners, a public company with approximately $500 million in revenues. In this position, Ms. Felch directed the treasury, tax, financial planning and analysis, credit and collections and risk management functions. Earlier, Ms. Felch served American Pharmaceutical Partners as Senior Director of Corporate Accounting and Director in General Accounting and Tax, where her responsibilities included internal and external financial reporting, tax, treasury, financial planning, credit and risk management.
Previously, Ms. Felch was an executive with Fujisawa USA, the subsidiary of a major Japanese pharmaceutical company, where she served as Director of Corporate Tax as well as in other financial positions. American Pharmaceutical Partners purchased Fujisawa’s generic business.
Earlier, Ms. Felch was Tax manager for LyphoMed, Inc. a generic pharmaceutical manufacturing venture that grew from $1 million in revenues to more than $200 million in seven years and was acquired by Fujisawa.
Ms. Felch is a CPA and holds a BA degree in accounting from Lakeland College in Sheboygan, Wisconsin and a Masters of Science degree in Taxation from DePaul University in Chicago.
The Female Health Company, based in Chicago, owns certain worldwide rights to FC Female Condom(R) including patents which have been issued in the United States, United Kingdom, Japan, France, Italy, Germany, Spain, The People’s Republic of China, Canada, New Zealand, South Korea and Australia. FC Female Condom(R) is the only available product controlled by a woman that protects against sexually transmitted diseases including HIV/AIDS, and unintended pregnancy.
“Safe Harbor” statement under the Private Securities Litigation Reform Action of 1995: The statements in this release which are not historical fact are forward-looking statements based upon the Company’s current plan and strategies, and reflect the Company’s current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company’s press releases, shareholder communication and Securities and Exchange Commission filings. Actual events affecting the Company and the impact of such events on the Company’s operations may vary from those currently anticipated.
For more information about the Female Health Company, dial toll-free via fax, 1-800-PRO-INFO and enter company code “FHCO”. Also, visit the Company’s web site at http://www.femalehealth.com and http://www.femalecondom.org . If you would like to be added to an e-mail alert list, please send an e-mail to FHCInvestor@aol.com .
Female Health Company
CONTACT: Investors Contact, William R. Gargiulo, Jr., +1-231-526-1244,Business-Product Contact, Mary Ann Leeper, Ph.D., +1-312-595-9123, or MediaContact, Bryan Callahan, +1-202-729-4255, all for Female Health Company
